top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hCD3E mice
Strain Name
C57BL/6-Cd3etm2(CD3E)Bcgen/Bcgen
Common Name  B-hCD3E mice
Background C57BL/6 Catalog number  110008
Related Genes 
CD3E (CD3E molecule)
NCBI Gene ID
12501

Protein expression analysis


from clipboard


Strain specific CD3E expression analysis in homozygous B-hCD3E mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hCD3E mice, and analyzed by flow cytometry with species-specific anti-CD3E antibody. Mouse CD3E was exclusively detectable in WT mice. Human CD3E were exclusively detectable in homozygous B-hCD3E but not WT mice.


Phenotypic analysis 


from clipboard


Thymus and spleen were isolated and weighed from C57BL/6 and B-hCD3E mice (n=6). There was no significant difference in spleen weight between C57BL/6 and B-hCD3E mice. However, the thymus weight in B-hCD3E mice is slightly lower than that of WT C57BL/6 mice.


Analysis of leukocytes subpopulation in B-hCD3E mice


from clipboard



Analysis of leukocytes subpopulation in B-hCD3E mice - Thymus
Thymocytes were isolated from 8-week-old C57BL/6 and B-hCD3E mice (n=6). The proportion of leukocytes subpopulation was tested by flow cytometry. As a result, the expression profile of leukocytes subpopulation in homozygous B-hCD3E mice is similar to that in the C57BL/6 mice, indicating that differentiation of T, B, NK, Monocyte, DC and macrophage cells are not affected by the humanization of hCD3E.



Analysis of leukocytes subpopulation in B-hCD3E mice

from clipboard


from clipboard



Analysis of T cell subpopulation in B-hCD3E mice – Thymus
The lymphocytes were isolated from thymus in 8-week-old C57BL/6 and B-hCD3E mice (n=6). The proportion of T cells subpopulation was tested by flow cytometry. As a result, the expression profile of lymphocyte subpopulation in homozygous B-hCD3E mice is similar to that in the C57BL/6 mice, indicating that T cell differentiation is not affected by the humanization of hCD3E.



Analysis of thymus lymphocyte subpopulation in B-hCD3E mice

from clipboard

Thymocytes were isolated from 4-week-old C57BL/6 and B-hCD3E mice (n=4). A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as shown here. B. Results of FACS analysis. The Percentage of CD4, CD8 T cells in B-hCD3E mice was similar to that of C57BL/6 mice, indicating that T cell subpopulation in thymus of B-hCD3E mice was not significantly affected by Cd3e gene humanization.


Analysis of leukocytes subpopulation in B-hCD3E mice


from clipboard

from clipboard


Analysis of leukocytes subpopulation in B-hCD3E mice -spleen
Splenocytes were isolated from 8-week-old C57BL/6 and B-hCD3E mice (n=6). The proportion of leukocytes subpopulation was tested by flow cytometry. As a result, the expression profile of leukocytes subpopulation in homozygous B-hCD3E mice is similar to that in the C57BL/6 mice, indicating that differentiation of T, B, NK, Monocyte, DC and macrophage cells are not affected by the humanization of hCD3E.


Analysis of leukocytes subpopulation in B-hCD3E mice



from clipboard

from clipboard


Analysis of T cell subpopulation in B-hCD3E mice – spleen.
The lymphocytes were isolated from spleen in 8-week-old C57BL/6 and B-hCD3E mice (n=6). The proportion of T cells subpopulation was tested by flow cytometry. As a result, the expression profile of lymphocyte subpopulation in homozygous B-hCD3E mice is similar to that in the C57BL/6 mice, indicating that T cell differentiation is not affected by the humanization of hCD3E.



Analysis of spleen lymphocyte subpopulation in B-hCD3E mice


from clipboard


Analysis of lymphocyte subpopulations by FACS.

The lymphocyte were isolated from C57BL/6 and B-hCD3E mice (n=4). Single live cells were gated for CD45 population and used for further analysis as indicated here. Percent of T cell , B cell and Treg cell in homozygous B-hCD3E mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hCD3E in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in spleen.


Analysis of B and T cell subpopulation by FACS – Spleen, PBMC, Lymph node


from clipboard

Lymphocytes were isolated from spleen, peripheral blood and lymph node of C57BL/6 and B-hCD3E mice (n=4). Flow cytometry analysis was performed to assess Lymphocytes subpopulations. Single live cells were gated for CD45 population and used for further analysis as shown here. The Percentage of T, B, cells in B-hCD3E mice was similar to that of C57BL/6 mice.


Analysis of T cell activation stimulated with anti-CD3 antibody in vitro


from clipboard


T cells (2.5×106) were isolated from splenocytes of C57BL/6 and B-hCD3E mice (n=4), and were incubated in the presence of anti-CD3E antibody (2ug/ml) and anti-mCD28 antibody (5ug/ml) for 48h. T cell proliferation was tested by flow cytometry. T cell activation in B-hCD3E mice was significantly up-regulated by anti-hCD3E antibody, similar to the activation level shown in C57BL/6 mice treated with anti-mCD3E antibody.


Analysis of T cell activation stimulated with anti-CD3 antibody in vitro


from clipboard


T cells (2.5×106) were isolated from the splenocytes of C57BL/6 and B-hCD3E mice (n=4), and incubated in the presence of anti-CD3E antibody (2ug/ml) and anti-mCD28 (5ug/ml) for 24h, 48h and 72h. T cell proliferation was measured by flow cytometry. T cell activation in B-hCD3E mice was significantly up-regulated by anti-hCD3 antibody, similar to the activation level shown in the anti-mCD3 antibody-treated C57BL/6 mice, indicating that Cd3e humanization in B-hCD3E mice does not affect T cell activation in spleen.


Analysis of T cell activation stimulated with anti-CD3 antibody in vitro

from clipboard


T cells (2.5×106) were isolated from the splenocytes of C57BL/6 and B-hCD3E mice (n=4), and incubated in the presence of anti-CD3E antibody (2ug/ml)  and anti-mCD28 antibody (5ug/ml) for 24h, 48h and 72h. IFN-γ and IL-2 production were tested using ELISA method. Concentration of IFN-γ and IL-2 in B-hCD3E mice was similar to that of C57BL/6 mice, indicating that Cd3e humanization in B-hCD3E mice does not affect T cell activation in spleen.


Analysis of T cell activation stimulated with anti-CD3 antibody ex vivo


from clipboard


C57BL/6 and B-hCD3E mice were injected intraperitoneally with anti-CD3E antibody (10ug/mouse). After 24h, T cells were isolated from splenocytes of C57BL/6 and B-hCD3E mice (n=4). T cell proliferation was measured by flow cytometry. T cell activation in B-hCD3E mice was significantly up-regulated by anti-hCD3E antibody, similar to the activation level in the anti-mCD3E antibody-treated C57BL/6 mice, demonstrating that introduction of hCD3E in place of its mouse counterpart does not affect T cell activation in spleen.


Analysis of T cell activation stimulated with anti-CD3 antibody ex vivo

from clipboard


C57BL/6 and B-hCD3E mice were injected intraperitoneally with anti-CD3E antibody (10ug/mouse). After 48h, T cells were isolated from splenocytes of C57BL/6 and B-hCD3E mice (n=4). T cell proliferation was measured by flow cytometry. T cell activation in B-hCD3E mice was significantly down-regulated, similar to the activation level in the anti-mCD3 antibody-treated C57BL/6 mice, demonstrating that introduction of hCD3E in place of its mouse counterpart does not affect T cell activation in spleen.


Cytotoxicity evaluation of CD3-PD-L1 bispecific antibody in vitro 

from clipboard


B-hCD3E mouse spleen cells were mixed with MC38-hPD-L1 and various concentrations of CD3-PD-L1 bispecific antibodies were added. The killing activity was detected after 48 hours. When effector cells : target  cells (E:T) =10:1,the EC50 of CD3-PD-L1 bispecific antibodies activity was 452.4 ng/mL; When E:T=20:1,the EC50 of CD3-PD-L1 bispecific antibodies activity was 144.2 ng/mL


Blood routine test in B-hCD3E mice


from clipboard


Complete blood count (CBC). 
Blood from female C57BL/6 and B-hCD3E mice (n=8, 7-week-old) were collected and analyzed for CBC. There was no differences among any measurement between C57BL/6 and B-hCD3E mice, indicating that introduction of hCD3E in place of its mouse counterpart does not change blood cell composition and morphology. Values are expressed as mean ± SEM.

Blood chemistry of B-hCD3E mice

from clipboard


Blood chemistry tests of B-hCD3E mice. 
Serum from female C57BL/6 and B-hCD3E mice (n=8, 7-week-old) were collected and analyzed for levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). The measurement results were similar between C57BL/6 and B-hCD3E mice, indicating that introduction of hCD3E in place of its mouse counterpart does not change ALT and AST levels or health of liver. Values are expressed as mean ± SEM.


CD3 Abs efficacy evaluation 


from clipboard

Murine colon cancer MC38 cells were subcutaneously implanted into C57BL/6 (A) and B-hCD3E (B) mice. Mice were grouped when the tumor size was approximately 150±50mm3 (n=5).In B-hCD3E mice, mPD-1 antibody significantly inhibited tumor growth, indicating their T cells function normally. However, in B-hCD3E mice, tumor growth was faster after anti-hCD3E antibody treatment, which may be caused by activation induced cell death (AICD). As a result, the B-hCD3E mouse model is a powerful tool for in vivo CD3 antibody pharmacological efficacy studies.


T cell activation in CD3 Abs efficacy evaluation


from clipboard

the proportion of T cells was significantly decreased due to the activation induced cell death (AICD) effect caused by CD3E antibody treatment. However, the proportion of T cells has no significant change in the anti-mPD-1 antibody group. (A) Compared with hlgG Ab , there is no significant difference in the percentage of CD19+ cells in total CD45+ cells after hCD3 Ab or mCD3 Ab treatment. (B) Compared with hlgG Ab, the percentage of TCR-β positive cells was significantly decreased after treatment with hCD3 Ab in the humanized mice.


Percentage of CD4+ and CD8+ cells after hCD3 antibody treatment

from clipboard


(A) Compared with hlgG Ab, the percentage of CD4+ T cells in the blood decreased significantly after hCD3E Ab treatment. (B) Compared with hlgG Ab, the percentage of CD8+ T cells in the blood was significantly reduced after hCD3E Ab treatment. 


hCD3 Abs efficacy evaluation with two doses

from clipboard

Murine colon cancer MC38 cells were subcutaneously implanted into B-hCD3E mice. Mice were divided into control and treatment groups(n=5) when tumon size was approximately 150±50 mm3. High doses of hCD3E antibodies resulted in faster tumor growth due to activation induced cell death (AICD), confirming that the B-hCD3E mouse model is a powerful tool for in vivo anti-hCD3 antibody pharmacological efficacy study. (A) Tumor average volume ±SEM, (B) Mice average weight±SEM.


Dose-dependent T cell depletion caused by hCD3 Ab treatment

from clipboard


The ratio of B and T cells in the blood was detected by flow cytometry. Lymphocytes were isolated from peripheral blood at the end of the experiment. In the treatment group, the proportion of T cells was significantly reduced due to the activation induced cell death (AICD) effect caused by CD3E antibody treatment.

Tumor marker Ab (X) efficacy evaluation with two doses

from clipboard


Antitumor activity of Antibody X in B-hCD3E mice. (A) High-dose Antibody X inhibited MC38 tumor growth in B-hCD3E mice(n=5). Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hCD3E mice. Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with Antibody X with doses and schedules indicated in panel ; (B) Body weight changes during treatment. As shown in panel A, high-dose Antibody X were efficacious in controlling tumor growth in B-hCD3E mice, demonstrating that the B-hCD3E mice provide a powerful preclinical model for in vivo evaluation of Antibody X . Values are expressed as mean ±SEM


T cell activation in tumor marker Ab (X) efficacy evaluation with two doses

from clipboard


The ratio of B and T cells in the blood of mice was detected by flow cytometry. Lymphocytes were isolated from peripheral blood at the experimental end point. In the treatment group, the ratio of B and T cells did not change significantly. 


Blinatumomab efficacy evaluation

from clipboard


MC38-hCD19 cells were  implanted subcutaneously into B-hCD3E mice. The mice were divided into control and treatment groups (n=6) when the tumor size was about 150±50 mm3. High-dose hCD3E antibody (Blinatumomab) significantly inhibited tumor growth, confirming that the B-hCD3E mouse model is a powerful tool for evaluating the efficacy of bispecific antibody against hCD3E in vivo.(A) Tumor average volume ± SEM, (B) Mice average weight ±SEM.

CD3E BsAb Efficacy Evaluation 


from clipboard

Antitumor activity of CD3E BsAb in B-hCD3E mice. (A) CD3E BsAb inhibited tumor growth in B-hCD3E mice. (B) Body weight changes during treatment. As shown in panel A, CD3E BsAb with different doses were efficacious in controlling tumor growth in B-hCD3E mice, demonstrating that the B-hCD3E mice provide a powerful preclinical model for in vivo evaluation of CD3E BsAb. Values are expressed as mean ± SEM.


CD3-hEpCAM BsAb efficacy evaluation

from clipboard



MC38-hEpCAM cells were implanted subcutaneously into B-hCD3E mice. The mice were divided into control and treatment groups when the tumor size was about 100±20 mm3. The results show that the anti-hCD3E/hEpCAM bispecific antibody has a moderate degree of antitumor activity compared to the control group. The data also show that anti-mouse CD4 (a CD4-depleting antibody) enhances the antitumor activity of the bispecific anti-hCD3E/hEpCAM antibody.